IMIQUIMOD cream

Land: USA

Språk: engelska

Källa: NLM (National Library of Medicine)

Aktiva substanser:

IMIQUIMOD (UNII: P1QW714R7M) (IMIQUIMOD - UNII:P1QW714R7M)

Tillgänglig från:

Physicians Total Care, Inc.

INN (International namn):

IMIQUIMOD

Sammansättning:

IMIQUIMOD 50 mg in 1 g

Administreringssätt:

TOPICAL

Receptbelagda typ:

PRESCRIPTION DRUG

Terapeutiska indikationer:

Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Imiquimod Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years or older. Imiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy. [see Use in Specific Populations (8.4) ]. The safety and efficacy of imiquimod cream in immunosuppressed patients have not been established. Imiquimod Cream should be used with caution in patients with pre-existing autoimmune conditions. The efficacy and safety of imiquimod cream have not been established for patients with Basal Cell Nevus Syndrome or Xeroderma Pigmentosum. None. Note:The Maximum Recommended Human Dose (MRHD) was set at 2 packets per treatment of imiquimod cream (25 mg imiquimod) for the animal multiple of human exposure ratios presented in t

Produktsammanfattning:

Imiquimod cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 24 packets   NDC 54868-6179-0 . Store at 4° - 25°C (39° - 77°F)         Avoid freezing. Keep out of reach of children.

Bemyndigande status:

Abbreviated New Drug Application

Produktens egenskaper

IMIQUIMOD - IMIQUIMOD CREAM
PHYSICIANS TOTAL CARE, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
FO UG E RA
IMIQUIMOD CREAM 5%
R ONLY
[I MI WEH MOD]
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
IMIQUIMOD CREAM SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR IMIQUIMOD CREAM.
IMIQUIMOD CREAM
FOR TOPICAL USE ONLY
INITIAL U.S. APPROVAL 1997
INDICATIONS AND USAGE
Imiquimod Cream is indicated for the topical treatment of:
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic
keratoses (AK) on the face or scalp in immunocompetent
adults (1.1)
External genital and perianal warts/condyloma acuminata in patients 12
years old or older (1.3) Limitations of Use:
Efficacy was not demonstrated for molluscum contagiosum in children
aged 2-12 (1.4, 8.4)
DOSAGE AND ADMINISTRATION
Imiquimod Cream is not for oral, ophthalmic, or intravaginal use. (2)
Actinic keratosis: 2 times per week for a full 16 weeks (2.1)
External genital warts (EGW): 3 times per week until total clearance
or a maximum of 16 weeks (2.3)
DOSAGE FORMS AND STRENGTHS
Imiquimod Cream 5% is supplied in a box containing 24 single-use
packets, each of which contains 250 mg of the
cream, equivalent to 12.5 mg of imiquimod. (3)
CONTRAINDICATIONS
None (4)
WARNINGS AND PRECAUTIONS
Intense local inflammatory reactions can occur (e.g., skin weeping,
erosion). Dosing interruption may be required (2,
5.1, 6)
Flu-like systemic signs and symptoms including malaise, fever, nausea,
myalgias and rigors may occur. Dosing
interruption may be required (2, 5.2, 6)
Avoid exposure to sunlight and sunlamps. Wear sunscreen daily (5.3).
Safety and efficacy have not been established for repeat courses of
treatment to the same area for AK. (5.4)
Treatment of urethral, intra-vaginal, cervical, rectal or intra-anal
viral disease is not recommended. (5.6)
Safety and efficacy in immunosuppressed patients have not been
established (1.5)
ADVERSE REACTIONS
Most common adverse reactions (incidence >28%) are application site
reactions or local skin r